Addition of Erlotinib to Sorafenib Does Not Improve Survival in Advanced Liver Cancer

Share this content:

the Cancer Therapy Advisor take:

According to a new study published in the Journal of Clinical Oncology, researchers have found that the addition of erlotinib to sorafenib does not improve survival in patients with advanced hepatocellular carcinoma.

For the international, double-blind, placebo-controlled phase 3 study, researchers sought to determine whether adding erlotinib to sorafenib would improve clinical outcomes for patients with advanced hepatocellular carcinoma.

Researchers enrolled 720 patients with advanced hepatocellular carcinoma and underlying Child-Pugh class A liver cirrhosis and randomly assigned them to receive sorafenib plus either placebo or erlotinib. All patients had not received systemic treatment prior to the study.

Results showed that the median overall survivals were similar across both arms (9.5 months in the sorafenib plus erlotinib group versus 8.5 months in the sorafenib plus placebo group; HR = 0.929; P = 0.408). The median time to progression was also similar in both arms (3.2 months versus 4.0 months; HR = 1.135; P = 0.18).

The overall response rate was slightly higher in the sorafenib plus erlotinib arm (P = 0.102), but the disease control rate was significantly lower in that arm (P = 0.021). In regard to safety, adverse events were similar in both arms.

Drinking More Coffee May Lower Liver Cancer Risk
Addition of erlotinib to sorafenib does not improve survival in patients with advanced hepatocellular carcinoma.
The authors aimed to compare the clinical outcomes of sorafenib plus either erlotinib or placebo in patients with advanced hepatocellular carcinoma (HCC) in a multicenter, multinational, randomized, phase III trial. Adding erlotinib to sorafenib did not improve survival in patients with advanced HCC.
READ FULL ARTICLE From Mdlinx

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters